Bristol Myers Squibb cash flow statement

In fiscal 2025, Bristol Myers Squibb's operations generated $14.16bn of cash; it spent $1.31bn on capital projects, leaving free cash flow of $12.85bn. It returned $5.04bn in dividends.

Cash flow statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Bristol Myers Squibb: cash flow statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Cash from operations	4.1	4.5	4.8	6.9	3.5	3.1	2.1	3.1	5.3	7.1	8.2	14.1	16.2	13.1	13.9	15.2	14.2	10.7
Depreciation and amortisation	0.5	0.6	0.6	0.7	0.8	0.5	0.4	0.4	0.8	0.6	1.7	10.4	10.7	10.3	9.8	9.6	4.0	1.9
Stock-based pay	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.4	0.8	0.6	0.5	0.5	0.5	0.6	0.6
Capital spending	0.7	0.4	0.4	0.5	0.5	0.5	0.8	1.2	1.1	1.0	0.8	0.8	1.0	1.1	1.2	1.2	1.3	1.4
Free cash flow	3.3	4.1	4.5	6.4	3.0	2.6	1.3	1.8	4.2	6.1	7.4	13.3	15.2	11.9	12.7	13.9	12.8	9.3
Free cash flow after stock pay	3.2	3.9	4.3	6.2	2.8	2.4	1.1	1.6	4.0	5.9	6.9	12.5	14.7	11.5	12.1	13.4	12.3	8.7
Dividends paid	2.5	2.2	2.3	2.3	2.3	2.4	2.5	2.5	2.6	2.6	2.7	4.1	4.4	4.6	4.7	4.9	5.0	5.1
Share buybacks	—	0.6	1.2	2.4	0.4	—	—	0.2	2.5	0.3	7.3	1.5	6.3	8.0	5.2	0.0	0.0	—

US$ millions unless shown otherwise. Fiscal quarters.

Bristol Myers Squibb: cash flow statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Cash from operations	4,439	1,954	3,917	6,311	1,974	1,104	3,393	4,181
Depreciation and amortisation	1,880	1,012	165	159	977	594	139	151
Stock-based pay	120	144	138	139	133	146	135	138
Capital spending	378	260	361	320	370	347	305	344
Free cash flow	4,061	1,694	3,556	5,991	1,604	757	3,088	3,837
Free cash flow after stock pay	3,941	1,550	3,418	5,852	1,471	611	2,953	3,699

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BMY vs NVO BMY vs GSK AZN vs BMY BMY vs PFE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Bristol Myers Squibb's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bristol Myers Squibb.